PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2006 | 1 | 3 | 306-312
Article title

Fatal outcome of pyoderma gangrenosum with multiple organ involvement and partially responding to Infliximab

Content
Title variants
Languages of publication
EN
Abstracts
EN
Pyoderma gangrenosum is an inflammatory dermatosis of uncertain etiology, often associated with chronic inflammatory bowel or rheumatoid disease. It predominantly affects the skin. A systemic organ involvement caused by aseptic neutrophilic abscesses, however, fundamentally influences the prognosis.A patient with idiopathic pyoderma gangrenosum insufficiently responded to a conventional immune suppressive therapy and the disease proceeded aggressively. During treatment with Infliximab, partial remission was achieved intermediately. However, a recurring endocarditis, led to a lethal outcome of this patient.
Publisher
Journal
Year
Volume
1
Issue
3
Pages
306-312
Physical description
Dates
published
1 - 9 - 2006
online
23 - 8 - 2006
References
  • [1] P. von den Driesch: “Pyoderma gangrenosum: a report of 44 cases with follow-up”, Br. J. Dermatol., Vol. 137, (1997), pp. 1000–1005. http://dx.doi.org/10.1046/j.1365-2133.1997.20022083.x[Crossref]
  • [2] I. Riahi, M. Mokni, S. Haouet et al.: “Pyoderma gangrenosum. 15 cases”, Ann. Med. Interne., Vol. 152, (2001), pp. 3–9.
  • [3] M. Vadillo, A. Jucgla, D. Podzamczer et al.: “Pyoderma gangrenosum with liver, spleen and bone involvement in a patient with chronic myelomonocytic leukaemia”, Br. J. Dermatol., Vol. 141, (1999), pp. 541–543. http://dx.doi.org/10.1046/j.1365-2133.1999.03055.x[Crossref]
  • [4] E. Miserocchi, G. Modorati, C.S. Foster et al.: “Ocular and extracutaneous involvement in pyoderma gangrenosum”, Ophthalmology, Vol. 109, (2002), pp. 1941–1943. http://dx.doi.org/10.1016/S0161-6420(02)01165-X[Crossref]
  • [5] V.G. Hubbard, A.C. Friedmann and P. Goldsmith: “Systemic pyoderma gangrenosum responding to infliximab and adalimumab”, Br. J. Dermatol., Vol. 152, (2005), pp. 1059–1061. http://dx.doi.org/10.1111/j.1365-2133.2005.06467.x[Crossref]
  • [6] G. Koester, A. Tarnower, D. Levisohn et al.: “Bullous pyoderma gangrenosum”, J. Am. Acad. Dermatol., Vol. 29, (1993), pp. 875–878. http://dx.doi.org/10.1016/0190-9622(93)70261-Q[Crossref]
  • [7] A. Hernandez-Martin, D. Arias-Palomo, G. Hermida et al.: “Oral pyoderma gangrenosum” Br. J. Dermatol., Vol. 149, (2003), pp. 663–664. http://dx.doi.org/10.1046/j.1365-2133.2003.05503.x[Crossref]
  • [8] K.S. Kennedy, M.L. Prendergast and C.D. Sooy: “Pyoderma gangrenosum of the oral cavity, nose, and larynx”, Otolaryngol. Head Neck Surg., Vol. 97, (1987), pp. 487–490.
  • [9] M.H. Tan, M. Gordon, O. Lebwohl et al.: “Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody”, Arch. Dermatol., Vol. 137, (2001), pp. 930–933.
  • [10] M. Regueiro, J. Valentine, S. Plevy et al.: “Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease”, Am. J. Gastroenterol., Vol. 98, (2003), pp. 1821–1826. http://dx.doi.org/10.1111/j.1572-0241.2003.07581.x[Crossref]
Document Type
Publication order reference
YADDA identifier
bwmeta1.element.-psjd-doi-10_2478_s11536-006-0024-9
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.